Use of hydroxyurea to alter drug resistance of human tumor cells

  • Carla Van Den Berg
  • Daniel D. Von Hoff
Part of the Cancer Treatment and Research book series (CTAR, volume 78)


Tumor resistance to chemotherapeutic agents is a commonly observed problem in oncology patient care. The mechanisms that tumor cells develop to escape toxicity from drugs are poorly characterized. One of the most important factors for our lack of understanding of drug resistance is that patient tumor specimens are infrequently studied directly. Most of our knowledge has been obtained from in vitro studies with tumor cell lines, with a limited number of variables affecting the outcome. Using tumor cell lines, information has been acquired to formulate mechanisms whereby cells may survive chemotherapeutic interventions.


Gene Amplification Adenosine Deaminase Dihydrofolate Reductase Drug Resistance Gene Thymidylate Synthetase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Benner SE, Wahl GM, Von Hoff DD. Double minute chromosomes and homogeneously staining regions in tumors taken directly from patients versus human tumor cell lines. Anticancer Drugs 2:11–25, 1991.CrossRefPubMedGoogle Scholar
  2. 2.
    Gebhart E, Bruderlein S, Tulusan AH, Maillot KV, Birkmann J. Incidence of double minutes, Cytogenetic equivalents of gene amplification in human carcinoma cells. Int J Cancer 34:369–373, 1984.CrossRefPubMedGoogle Scholar
  3. 3.
    McGill JR, Meador R, Forseth B, Davidson K, Walsh J, Von Hoff D. Evidence that gene amplification occurs frequently in breast and ovarian cancers. Breast Cancer Res Treat 23:174, 1992.Google Scholar
  4. 4.
    Nielson JL, Walsh JT, Degen DR, Drabek SM, McGill JR, Von Hoff DD. Evidence of gene amplification in the form of double minute chromosomes is frequently observed in lung cancer. Cancer Genet Cytogenet 65:120–124, 1993.CrossRefGoogle Scholar
  5. 5.
    Seeger RC, Brodeur GM, Sather H. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 313:1111–1116, 1985.CrossRefPubMedGoogle Scholar
  6. 6.
    Brodeur GM, Seeger RC. Amplification of N-myc in untreated human neuroblastomas correlated with advanced stage disease. Science 244:1121–1124, 1989.CrossRefGoogle Scholar
  7. 7.
    Slamon DJ, Godolphin W, Jones LA. Sudies of HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707–712, 1989.CrossRefPubMedGoogle Scholar
  8. 8.
    Slamon DJ, Clark GM, Wong SG, Levin WJ, Ulrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182, 1987.CrossRefPubMedGoogle Scholar
  9. 9.
    Berns MJ, Klijn JG, Hensen-Logmans SC, Rodenburg CJ, van der Burg ME, Foekens JA. Receptors for hormones and growth factors and (onco)-gene amplification in human ovarian cancer. Int J Cancer 52:218–224, 1992.CrossRefPubMedGoogle Scholar
  10. 10.
    Christen RD, Shalinsky DR, Howell SB. Enhancement of the loss of multiple drug resistance by hydroxyurea. Semin Oncol 19(Suppl 9):94–100, 1992.PubMedGoogle Scholar
  11. 11.
    Maurer BJ, Lai E, Hamkalo BA, Hood L, Attardi G. Novel microscopic extrachromosomal elements containing amplified genes in human cells. Nature 327:434–437,1987.CrossRefPubMedGoogle Scholar
  12. 12.
    Meese EU, Horwitz SB, Trent JM. Evidence for linear extrachromosomal elements mediating gene amplification in the multidrug-resistant J774.2 murine cell line. Cancer Genet Cytogen 59:20–25, 1992.CrossRefGoogle Scholar
  13. 13.
    Carroll SM, DeRose ML, Gaudray P, et al. Double minute chromosomes can be produced from precursors derived from chromosomal deletion. Mol Cell Biol 8:1525–1533, 1988.PubMedGoogle Scholar
  14. 14.
    Snapka RM, Varshavshy A. Loss of unstably amplified dihydrofolate reductase genes from mouse cells is greatly accelerated by hydroxyurea. Proc Natl Acad Sci USA 80:7533–7537, 1983.CrossRefPubMedGoogle Scholar
  15. 15.
    Ruiz JC, Choi K, Von Hoff DD, Robinson IB, Wahl GM. Autonomously replicating episomes contain mdrl genes in a multidrug-resistant human cell line. Mol Cell Biol 9:109–115, 1989.PubMedGoogle Scholar
  16. 16.
    Stark GR, Wahl GM. Gene amplification. Annu Rev Biochem 53:447–491, 1984.CrossRefPubMedGoogle Scholar
  17. 17.
    Hamlin JL, Milbrandt JD, Heintz NH, Azizkhan JC. DNA sequence amplification in mammalian cells. Int Rev Cytol 90:31–82, 1984.CrossRefPubMedGoogle Scholar
  18. 18.
    Schimke RT. Gene amplification in cultured animals cells. Cell 37:705–713, 1984.CrossRefPubMedGoogle Scholar
  19. 19.
    Mayer KH, Opal SM, Medeiros AA. Mechanisms of antibiotic resistance. In Mandell GL, Douglas RG, Bennett JE (eds), Principles and Practice of Infectious Disease. Churchill Livingstone: New York, pp 218–219.Google Scholar
  20. 20.
    Clowes BC. Molecular structure of bacterial plasmids. Bacteriol Rev 36:361–405, 1972. Colvin M, Bono VH. The enzymatic reduction of hydroxyurea to urea by mouse liver. Cancer Res 30:1516-1519, 1970.PubMedGoogle Scholar
  21. 21.
    Schmitt R, Bernhard E, Mattes R. Characterization of Tnl721, a new transposon containing tetracycline resistance genes capable of amplification. Mol Gen Genet 172:53–62,1979.CrossRefPubMedGoogle Scholar
  22. 22.
    Mattes R, Burkardt HJ, Schmitt R. Repetition of tetracycline resistance determinant genes on R plasmid pRSD l in Escherichia coli. Mol Gen Genet 168:173–184, 1979.CrossRefPubMedGoogle Scholar
  23. 23.
    Fogel S, Welch JW. Tandem gene amplification mediates copper resistance in yeast. Proc Natl Acad Sci USA 79:5342–5346, 1982.CrossRefPubMedGoogle Scholar
  24. 24.
    Curt GA, Jolivet J, Carney DN, et al. Determinants of the sensitivity of human small-cell lung cancer cell lines to methotrexate. J Clin Invest 76:1323–1329, 1985.CrossRefPubMedGoogle Scholar
  25. 25.
    Biedler JL, Riehm H. Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radiographie, and cytogenetic studies. Cancer Res 30:1174–1184, 1970.PubMedGoogle Scholar
  26. 26.
    Vendrik CPJ, Bergers JJ, De Jong WH, Steerenberg PA. Resistance to cytostatic drugs at the cellular level. Cancer Chemother Pharmacol 29:413–429, 1992.CrossRefPubMedGoogle Scholar
  27. 27.
    Rossana C, Rao LG, Johnson LF. Thymidylate synthetase overproduction in 5-fluorodeo-xyuridine-resistant mouse fibroblasts. Mol Cell Biol 2:1118–1125, 1982.PubMedGoogle Scholar
  28. 28.
    Alt FW, Kellem RE, Bertino JR, Schimke RT. Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant variants of cultured murine cells. J Biol Chem 253:1357–1370, 1978.PubMedGoogle Scholar
  29. 29.
    Yeung CY, Riser ME, Kellems RE, Siciliano MJ. Increased expression of one of two adenosine deaminase alleles in human choriocarcinoma cell line following selection with adenine nucleosides. J Biol Chem 258:8330–8337, 1983.PubMedGoogle Scholar
  30. 30.
    Debatisse M, Berry M, Buttin G. Stepwise isolation and properties of unstable Chinese hamster cell variants that overproduce adenylate deaminase. Mol Cell Biol 2:1346–1353, 1982.PubMedGoogle Scholar
  31. 31.
    Carmen MD, Schornagel JH, Rivest RS. Resistance to methotrexate due to gene amplification in a patient with acute leukemia. J Clin Oncol 2:16–20, 1984.Google Scholar
  32. 32.
    Trent JM, Buick RN, Olson S, Horns RC, Schimke RT. Cytologic evidence of gene amplification in methotrexate resistant cells obtained from a patient with ovarian adenocarcinoma. J clin Oncol 2:8–15, 1984.PubMedGoogle Scholar
  33. 33.
    Choy BK, McClarty GA, Chan AK, Thelander L, Wright JA. Molecular mechanisms of drug resistance involving ribonucleotide reductase: hydroxyurea resistance in a series of clonally related mouse cell lines selected in the presence of increasing drug concentrations. Cancer Res 48:2029–2035, 1988.PubMedGoogle Scholar
  34. 34.
    Melera PW, Lewis JA, Biedler JL, Hession C. Antifolate-resistance Chinese hamster cells. J Biol Chem 255:7024–7028, 1980.PubMedGoogle Scholar
  35. 35.
    Giulotto E, Saito I, Stark GR. Structure of DNA formed in the first step of CAD gene amplification. EMBO 5:2115–2121, 1986.Google Scholar
  36. 36.
    Looney JE, Hamlin JL. Isolation of the amplified dihydrofolate reductase domain from methotrexate-resistant Chinese hamster ovary cells. Mol Cell Biol 7:569–577, 1987.PubMedGoogle Scholar
  37. 37.
    Masters J, Keeley B, Gay H, Attardi G. Variable content of a double minute chromosome is not correlated with degree of phenotype instability in methotrexate-resistant human cell lines. Mol Cell Biol 2:498–507, 1982.PubMedGoogle Scholar
  38. 38.
    Lewis JA, Biedler JL, Melera PW. Gene amplification accompanies low level increases in the activity of dihydrofolate reductase in antifolate-resisitant Chinese hamster lung cells containing abnormally banding chromosomes. J Cell Biol 94:418–424, 1982.CrossRefPubMedGoogle Scholar
  39. 39.
    Stahl F, Wettergren Y, Levan G. Amplicon structure in multidrug-resistant murine cells: a nonrearranged region of genomic DNA corresponding to large circular DNA. Mol Cell Biol 12:1179–1187, 1992.PubMedGoogle Scholar
  40. 40.
    Kaufman RJ, Brown PC, Schimke RT. Amplified dihydrofolate reductase genes in unstably methotrexate-resistant cells are associated with double minute chromosomes. Proc Natl Acad Sci USA 76:5669–5673, 1979.CrossRefPubMedGoogle Scholar
  41. 41.
    Brown PC, Tlsty TD, Schimke RT. Enhancement of methotrexate resistance and dihydrofolate reductase gene amplification by treatment of mouse 3T6 cells in hydroxyurea. Mol Cell Biol 3:1097–1107, 1983.PubMedGoogle Scholar
  42. 42.
    Ma C, Looney JE, Leu T-H, Hamlin JL. Organization and genesis of dihydrofolate reductase amplicons in the genome of a methotrexate-resistant Chinese hamster ovary cell line. Mol Cell Biol 8:2316–2127, 1988.PubMedGoogle Scholar
  43. 43.
    Gerlach JH, Kartner N, Bell DR, Ling V. Multidrug resistance. Cancer Surv 5:25–46, 1986.PubMedGoogle Scholar
  44. 44.
    Chow LMC, Wong AKC, Ullman B, Wirth DF. Cloning and functional analysis of extrachromosomally amplified multidrug resistance-like gene in Leishmania enriettii. Mol Biochem Parasitol 60:195–208, 1993.CrossRefPubMedGoogle Scholar
  45. 45.
    Ueda K, Cardarelli C, Gottesman MM, Pastan I. Expression of full-length cDNA for thehuman ‘MDR1’ gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA 84:3004–3008, 1987. Valentine WN, Paglia DE, Tartaglia AP, Galanz F. Science 195:783-785, 1977.CrossRefPubMedGoogle Scholar
  46. 46.
    Gros PJ, Neriah JM, Croop JM, Houseman DE. Isolation and expression of a complementary DNA that confers multidrug resistance. Nature (London) 323:728–731, 1986.CrossRefGoogle Scholar
  47. 47.
    Bender RA, Kornreich WD, Wodinsky I. Correlates of vincristine resistance in four murine tumor cell lines. Cancer Lett 15:335–341, 1982.CrossRefPubMedGoogle Scholar
  48. 48.
    Beck WT, Cirtain MC, Lefko JL. Energy-dependent reduced drug binding as a mechanism of Vinca alkaloid resistance in human leukemic lymphoblasts. Mol Pharmacol 24:485–492, 1983.PubMedGoogle Scholar
  49. 49.
    Bleyer WA, Frisby SA, Oliverio VT. Uptake and binding of vincristine by murine leukemia cells. Biochem Pharmacol 24:633–639, 1975.CrossRefPubMedGoogle Scholar
  50. 50.
    Gupta RS. Genetic, biochemical, and cross-resistance studies with mutants of Chinese hamster ovary cells resistant to the anticancer drugs, VM-26 and VP-213. Cancer Res 43:1568–1574, 1983.PubMedGoogle Scholar
  51. 51.
    De Bruijn MHL, Van der Bliek AM, Biedler JL, Borst P. Differential amplification and disproportionate expression of five genes in three multidrug-resistant Chinese hamster lung cell lines. Mol Cell Biol 6:4717–4722, 1986.PubMedGoogle Scholar
  52. 52.
    Robertson SM, Ling V, Stanners CP. Co-amplification of double minute chromosomes, multidrug resistance, and cell surface P-glycoprotein in DNA-mediated transformants of mouse cells. Mol Cell Biol 4:500–506, 1984.PubMedGoogle Scholar
  53. 53.
    Slovak ML, Lothstein L, Horwitz SB, Trent JM. Molecular/cytogenetic alterations accompanying the development of multidrug resistance in the J774. 2 murine cell line, leukemia 2:453–458, 1988.Google Scholar
  54. 54.
    Fojo AT, Whang-Peng J, Gottesman MM, Pastan I. Amplification of DNA sequences in human multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci USA 82:7661–7665, 1985.CrossRefPubMedGoogle Scholar
  55. 55.
    Schoenlein PV, Shen D, Barrett JT, Pastan I, Gottesman MM. Double minute chromosomes carrying the human multidrug resistance 1 and 2 genes are generated from dimerization of submicroscopic circular DNAs in colchicine-selected KB carcinoma cells. Mol Biol Cell 3:507–520, 1992.PubMedGoogle Scholar
  56. 56.
    Donehower RC, Myers CE, Chabner BA. New developments on the mechanisms of action of antineoplastic drugs. Life Sci 25:1–14, 1979.CrossRefPubMedGoogle Scholar
  57. 57.
    Chang AC, Nunberg JH, Kaufman RJ. Erlich HA, Schimke RT, Cohen SN. Phenotypic expression in E. coli of a DNA sequence coding for mouse dihydrofolate reductase. Nature 275:617–624, 1978.CrossRefPubMedGoogle Scholar
  58. 58.
    Johnston RN, Beverly SM, Schimke RT. Rapid spontaneous dihydrofolate reductase gene amplification shown by fluorescence-activated cell sorting. Proc Natl Acad Sci USA 80:3711–3715, 1983.CrossRefPubMedGoogle Scholar
  59. 59.
    Rath H, Tlsty T, Schimke RT. Rapid emergence of methotrexate resistance in cultured mouse cells. Cancer Res 44:3303–3306, 1984.PubMedGoogle Scholar
  60. 60.
    Biedler JL, Spengler BA. Metaphase chromosome anomaly: Association with drug resistance and cell-specific products. Science 191:185–188, 1976.CrossRefPubMedGoogle Scholar
  61. 61.
    Kleinberger T, Etkin S, Lavi S. Carcinogen-mediated methotrexate resistance and dihydrofolate reductase amplification in Chinese hamster cells. Mol Cell Biol 6:1958–1964, 1986.PubMedGoogle Scholar
  62. 62.
    Tlsty TD, Brown PC, Johnston R, Schimke RT. Enhanced frequency of generation of methotrexate resistance and gene amplification in cultured mouse and hamster cell lines. In Schimke RT (ed), Gene Amplification. Cold Spring Harbor Laboratory: Cold Spring Harbor, NY, 1982, pp 231–238.Google Scholar
  63. 63.
    Varshavsky A. Phorbol ester dramatically increases incidence of methotrexate-resistant mouse cells: possible mechanisms and relevance to tumor promotion. Cell 25:561–572, 1981.CrossRefPubMedGoogle Scholar
  64. 64.
    Johnston RN, Feder J, Hill AB, Sherwood SW, Schimke RT. Transient inhibition of DNA synthesis results in increased dihydrofolate reductase synthesis and subsequent increased DNA content per cell. Mol Cell Biol 6:3373–3381, 1986.PubMedGoogle Scholar
  65. 65.
    Nunberg JH, Kaufman RJ, Schimke RT, Urlaub G, Chasin LA. Amplified dihydrofolate reductase genes are localized to a homogeneously staining region of a single chromosome in a methotrexate-resistant Chinese hamster ovary cell line. Proc Natl Acad Sci USA 75:5553–5556, 1978.CrossRefPubMedGoogle Scholar
  66. 66.
    Schimke RT, Kaufman RJ, Alt FW, Kellems RF. Gene amplification and drug resistance in culture murine cells. Science 202:1051–1055, 1978.CrossRefPubMedGoogle Scholar
  67. 67.
    Brown PC, Beverley SM, Schimke RT. Relationship of amplified dihydrofolate reductase genes to double minute chromosomes in unstably resistant mouse fibroblast cell lines. Mol Cell Biol 1:1077–1083, 1981.PubMedGoogle Scholar
  68. 68.
    Hamkalo BA, Farnham PJ, Johnston R Schimke RT. Ultrastructural features of minute chromosomes in a methotrexate-resistant mouse 3T3 cell line. Proc Natl Acad Sci USA 82:1126–1130, 1985.CrossRefPubMedGoogle Scholar
  69. 69.
    Tyler-Smith C, Bostock CJ. Gene amplification in methotrexate-resistant mouse cells. J Mol Biol 153:237–256, 1981.CrossRefPubMedGoogle Scholar
  70. 70.
    Haber DA, Schimke RT. Unstable amplification of an altered dihydrofolate reductase gene associated with double-minute chromosomes. Cell 26:355–362, 1981.CrossRefPubMedGoogle Scholar
  71. 71.
    Zolg JW, Plitt JR, Chen G-X, Palmer S. Point mutations in the dihydrofolate reductasethymidylate synthetase gene as the molecular basis for pyromethamine resistance in Plasmodium falciparum. Mol Biochem Parasitol 36:253–262, 1989.CrossRefPubMedGoogle Scholar
  72. 72.
    Moran RG, Keyomarsi K, Patel R. Tumor cell responses to inhibition of thymidylate synthetase. In Rustum Y, McGuire J (eds), The Expanding Role of Folates and Fluor-opyrimidines in Cancer Chemotherapy, vol 244. New York, Plenum Press: 1988, pp. 71–80.CrossRefGoogle Scholar
  73. 73.
    Berger SH, Jenh C-H, Johnson LF, Berger FG. Thymidylate synthetase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells. Mol Pharmacol 28: 461–467, 1985.PubMedGoogle Scholar
  74. 74.
    Scalon KJ, Lu Y, Kashani-Sabet M, Ma JX, Newman E. Mechanisms for cisplatin-FUra synergism and cisplatin resistance in human ovarian cells both in vitro and in vivo. In Rustum Y, McGuire J (eds), The Expanding Role of Folates and Fluoropyrimidines in Cancer Chemotherapy, vol 244. Plenum Press: New York, 1988, 127–135.CrossRefGoogle Scholar
  75. 75.
    Clark JL, Berger SH, Mittelman A, Berger FG. Thymidylate synthetase gene amplification in colon tumor resistant to fiuoropyrimidine chemotherapy. Cancer Treat Rep 71:261–265, 1987.PubMedGoogle Scholar
  76. 76.
    Kashani-Sabet M, Rossi JJ, Lu Y, Ma JX, Chen J, Miyachi H, Scanion KJ. Detection of drug resistance in human tumors by in vitro enzymatic amplifcation. Cancer Res 48:5775–5778, 1988.PubMedGoogle Scholar
  77. 77.
    Padgett RA, Wahl GM, Stark GR. Structure of the gene for CAD, the multifunctional protein that initiates UMP synthesis in Syrian hamster cells. Mol Cell Biol 2:293–301, 1982. Peterson DS, Walliker D, Wellems TE. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthetase confers resistance to pyrimethamine in falciparum malaria. Proc Natl Acad Sci USA 85:9114-9118, 1988.PubMedGoogle Scholar
  78. 78.
    Grem JL, King SA, O’Dwyer PJ, Leyland-Jones B. Biochemistry and clinical activity of N-(phospho-acetyl)-L-aspartic acid: a review. Cancer Res 48:4441–4454, 1988.PubMedGoogle Scholar
  79. 79.
    Wahl GM, Padgett RA, Stark GR. Gene amplification causes overproduction of the first three enzymes of UMP synthesis in N-(phosphonacetyl)-L-aspartate-resistant hamster cells. J Biol Chem 254:8679–8689, 1979.PubMedGoogle Scholar
  80. 80.
    Ingolia DE, Yeung CY, Orengo IF, et al. Purification and characterization of adenosine deaminase from genetically enriched mouse cell line. J Biol Chem 260:13261–13267, 1985.PubMedGoogle Scholar
  81. 81.
    Kaufman RJ. Selection and coamplification of heterologous genes in mammalian cells. Methods Enzymol 185:537–566, 1990.CrossRefPubMedGoogle Scholar
  82. 82.
    Kaufman RJ, Murtha P, Ingolia DE, Yeung CY, Kellems RE. Selection and amplification of heterologous genes encoding adenosine deaminase in mammalian cells. Proc Natl Acad Sci USA 83:3136–3140, 1986.CrossRefPubMedGoogle Scholar
  83. 83.
    Yeung CY, Frayne EG, Al-Ubaidi MR, et al. Amplification and molecular cloning of murine adenosine deaminase gene sequences. J Biol Chem 258:15179–15185, 1983.PubMedGoogle Scholar
  84. 84.
    Yeung CY, Ingolia DE, Bobonis C, et al. Selective overproduction of adenosine deaminase in cultured mouse cells. J Biol Chem 258:8338–8345, 1983.PubMedGoogle Scholar
  85. 85.
    Debatisse M, Berry M, Buttin G. The potentiation of adenine toxicity to Chinese hamster cells by coformycin: suppression in mutants with altered regulation of purine biosynthesis of increased adenylate-deaminase activity. J Cell Physiol 106:1–11, 1981.CrossRefPubMedGoogle Scholar
  86. 86.
    Von Hoff DD McGill JR, Forseth BJ. Elimination of extrachromosomally amplified c-myc genes from human tumor cells reduces their tumorigenicity. Proc Natl Acad Sci USA 89:8165–8169, 1992.CrossRefGoogle Scholar
  87. 87.
    Bigner SH, Mark J, Burger PC. Specific chromosomal abnormalities in malignant gliomas. Cancer Res 88:405–411, 1988.Google Scholar
  88. 88.
    Snapka RM. Gene amplification as a target for cancer chemotherapy. Oncol Res 4:145–150, 1992.PubMedGoogle Scholar
  89. 89.
    Wahl GM. The importance of circular DNA in mammalian gene amplification. Cancer Res 49:1333–1340, 1989.PubMedGoogle Scholar
  90. 90.
    Von Hoff DD, Needham-Van Devanter DR, Yucel J, Windle BE, Wahl GM. Amplified human C-myc oncogenes localized to replicating submicroscopic circular DNA molecules. Proc Natl Acad Sci USA 85:4804–4808, 1988.CrossRefGoogle Scholar
  91. 91.
    Levan A, Levan G, Mandahl N. A new chromosome type replacing the double minutes in a mouse tumor. Cytogenet Cell Genet 20:12–23, 1978.CrossRefPubMedGoogle Scholar
  92. 92.
    Cowell JK. Double minutes and homogeneously staining regions: gene amplification in mammalian cells. Annu Rev Genet 16:21–59, 1982.CrossRefPubMedGoogle Scholar
  93. 93.
    Schimke RT, Brown PC, Kaufman RJ, McGrogan M, Slate DL. Chromosomal and extrachromosomal localization of amplified dihydrofolate reductase genes in cultured mammalian cells. Cold Spring Harbor Symp Quant Biol 45:785–796, 1981.CrossRefPubMedGoogle Scholar
  94. 94.
    Smith GR. Evolution of repeated DNA sequences by unequal crossover. Science 191:528–535, 1976.CrossRefPubMedGoogle Scholar
  95. 95.
    Von Hoff DD, Forseth B, Clare CN, Hansen KL, Van Devanter D. Double minutes arise from circular extrachromosomal DNA intermediates which integrate into chromosomal sites in human HL-60 leukemia cells J Clin Invest 85:1887–1895, 1990.Google Scholar
  96. 96.
    Lavialle C, Modjtahedi N, Lamonerie T, et al. The human breast carcinoma cell line SW 613-S: an experimental system to study tumor heterogeneity in the relation to c-myc amplification, growth factor production and other markers (Review). Anticancer Res 9:1265–1280, 1989.PubMedGoogle Scholar
  97. 97.
    Levan G, Stahl F, Wettergren Y. Gene amplification in the murine SEWA system. Mutat Res 276:285–290, 1992.CrossRefPubMedGoogle Scholar
  98. 98.
    Roelofs H, Schuuring E, Wiegant J, Michalides R, Giohart-Gassler M. Amplification of the 11q13 region in human carcinoma cell lines: mechanistic view. Genes Chrom Cancer 7:74–84, 1993.CrossRefPubMedGoogle Scholar
  99. 99.
    Van Devanter DR, Yirdaw G. Recombination between separate MYC amplification structures in COLO320 cells. Genes Chrom Cancer 6:190–197, 1993.CrossRefGoogle Scholar
  100. 100.
    Fakharzadeh SS, Rosenblum-Vos L, Murphy M, Hoffman EK, George DL. Structure and organization of amplified DNA on double minutes containing the mdm2 oncogene. Genomics 15:283–290, 1993.CrossRefPubMedGoogle Scholar
  101. 101.
    Tanaka K, Takechi M, Nishimura S, Oguma N, Kamade N. Amplification of c-MYC oncogene and point mutation of N-RAS oncogene point mutation in acute myelocytic leukemias with double minute chromosomes. Leukemia 7:469–471, 1993.PubMedGoogle Scholar
  102. 102.
    Von Hoff DD, McGill J, Davidson K, Wahl G. Hydroxyurea-induced loss of extrachromosomally amplified oncogenes is mediated through the formation of micronuclei, Proc Annu Meet Am Assoc Cancer Res 21:A2143, 1992.Google Scholar
  103. 103.
    Von Hoff DD, Waddelow T, Forseth B, Davidson K, Scott J, Wahl G. Hydroxyurea accelerates loss of extrachromosomally amplified genes from tumor cells. Cancer Res 51:6273–6279, 1991.Google Scholar
  104. 104.
    Wani MA, Snapka RM. Drug-induced loss of unstably amplified genes. Cancer Invest 8:587–593, 1990.CrossRefPubMedGoogle Scholar
  105. 105.
    Young CW, Schochetman G, Karnofsky DA. Hydroxyurea-induced inhibition of deoxynucleotide synthesis: studies in intact cells Cancer Res 27:526–534, 1967.Google Scholar
  106. 106.
    Rajewsky MF. Synchronization in vivo: kinetics for malignant cell system following temporary inhibition of DNA synthesis with hydroxyurea. Exp Cell Res 60:269–276, 1970.CrossRefPubMedGoogle Scholar
  107. 107.
    Stehman FB, Bundy BN, Thomas G, et al. Hydroxyurea versus misonidazole with radiation in cervical carcinoma: long-term follow-up of a Gynecologic Oncology Group trial. J Clin Oncol 11:1523–1528, 1993.PubMedGoogle Scholar
  108. 108.
    Dorr RT, Von Hoff DD. Drug monographs: Hydroxyurea. In Dorr RT, Von Hoff DD (eds), Cancer Chemotherapy Handbook, 2nd ed. Appleton & Lange: Norwalk, CT, 1994, 545–550.Google Scholar
  109. 109.
    Veale D, Cantwell BMJ, Kerr N, Upfold A, Harris AL. Phase 1 study of high-dose hydroxyurea in lung cancer. Cancer Chemother Pharmacol 21:53–56, 1988.CrossRefPubMedGoogle Scholar
  110. 110.
    Wani MA, Strayer JM, Snapka RM. Hypersensitivity to low-level cytotoxic stress in mouse cells with high levels of DHFR gene amplification. Anti-Cancer Drugs 8:587–593, 1990.Google Scholar
  111. 111.
    Cornforth MN, Goodwin EH. Transmission of radiation induced acentric chromosomal fragments to micronuclei in normal human fibroblasts. Radiat Res 126:210–217, 1991.CrossRefPubMedGoogle Scholar
  112. 112.
    Ford JH, Schultz CJ, Correli AT. Chromosome elimination in micronuclei: a common cause of hypoploidy. Am J Hum Genet 43:733–740, 1988.PubMedGoogle Scholar
  113. 113.
    Heddle JA, Cimino MC, Hayashi M, et al. Micronuclei as an index of cytogenetic damage: past, present, and future. Environ Mol Mutag 18:277–291, 1991.CrossRefGoogle Scholar
  114. 114.
    Hahn P, Kapp LN, Morgan WF, Painter RB. Chromosomal changes without DNA overproductions in hydroxyurea-treated mammalian cells: implications for gene amplification. Cancer Res 46:4607–4611, 1986.PubMedGoogle Scholar
  115. 115.
    Windle B, Draper BW, Yin Y, O’Gorman S, Wahl GM. A central role for chromosome breakage in gene amplification, deletion formation, and amplicon integration. Genes Dev 5:160–174, 1991.CrossRefPubMedGoogle Scholar
  116. 116.
    Von Hoff DD, McGill J, Davidson K, Forseth B, Ebraheim AA, Burris H. Preclinical leads for innovative uses for etoposide. Semin Oncol 19(Suppl 13):10–13, 1992.Google Scholar
  117. 117.
    Van Den Berg CL, McGill JR, Kuhn JG, et al. Pharmacokinetics of hydroxyurea in nude mice. Anti-Cancer Drugs 5:573–578, 1994.CrossRefPubMedGoogle Scholar
  118. 118.
    Fabricius E, Rajewsky MF. Determination of hydroxyurea in mammalian tissues and blood. Rev Eur Et Clin Biol 16:679–683, 1971.Google Scholar
  119. 119.
    Smith DC, Vaughan WP, Gwilt PR, Trump DL. A phase I trial of high-dose continuous-infusion hydroxyurea. Cancer Chemother Pharmacol 33:139–143, 1993.CrossRefPubMedGoogle Scholar
  120. 120.
    Plager J. The induction of transient increases in mitotic rate in murine tissues following prolonged intravenous infusions of hydroxyurea. Cell Tissue Kinet 8:517–528, 1975.PubMedGoogle Scholar
  121. 121.
    Philips FS, Sternberg SS, Schwartz HS, et al. HydroxyureaI. Acute cell death in proliferating tissues in rats. Cancer Res 27:61–74, 1967.PubMedGoogle Scholar
  122. 122.
    Bellet RJ, Haas CD, Kennedy J, Taylor S. Studies of hydroxyurea administered by continuous infusion: toxicity, pharmacokinetics, and cell synchronization. Cancer 46:455–462, 1980.CrossRefGoogle Scholar
  123. 123.
    Alitalo K, Schwab M. Oncogene amplification in tumor cells. Adv Cancer Res 47:235–281, 1986.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1995

Authors and Affiliations

  • Carla Van Den Berg
  • Daniel D. Von Hoff

There are no affiliations available

Personalised recommendations